BRCA1 and neoplasm: One could hypothesise that the notable improved outcome of the TNBC patients treated with capecitabine in the CREATE-X trial [5], limited to patients with residual disease after neoadjuvant treatment with anthracyclines, taxanes or both, was driven by patients enriched with non-BRCA1-like or resistant BRCA1-like tumours.